FilingReader Intelligence
CSPC licenses oral GLP-1 drug to Madrigal for $2.1bn
July 30, 2025 at 09:22 AM UTC•By FilingReader AI
CSPC Pharmaceutical Group granted Madrigal exclusive global rights to SYH2086, an oral GLP-1 receptor agonist, while retaining China rights for other oral GLP-1 products.
The deal includes $120 million upfront, potential milestones up to $1.955 billion, and double-digit royalties, totaling up to $2.075 billion. Preclinical data showed strong glucose-lowering and weight-loss effects.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1093•Hong Kong Exchange
News Alerts
Get instant email alerts when CSPC Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime